MyFinsight
Home
Blog
About
Contact
Back
Cash Flow
Semnur Pharmaceuticals, Inc. (SMNRW)
Semnur Pharmaceuticals, Inc. (SMNRW)
source: myfinsight.com
Download
Download image
Payments of deferred
offering costs
-$7,602K
Proceeds from related
party loans
$3,503K
Net cash provided by
financing activities
$2,753K
Canceled cashflow
$8,352K
Net change in cash
and cash...
$83K
Canceled cashflow
$2,670K
something is missing
-$7,602K
Repayment of promissory
notes
$750K
Stock-based compensation
$1,484K
Accounts payable
$511K
Accrued expenses
$451K
Net cash used in
operating activities
-$2,670K
Canceled cashflow
$2,446K
Net loss
-$4,576K
Prepaid expenses
$540K
Back